MacroGenics, Inc. (NASDAQ:MGNX) Stock Holdings Raised by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its stake in MacroGenics, Inc. (NASDAQ:MGNX) by 7.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 49,337 shares of the biopharmaceutical company’s stock after purchasing an additional 3,319 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned approximately 0.08% of MacroGenics worth $475,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its stake in MacroGenics by 349.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,174 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 5,577 shares in the last quarter. SG Americas Securities LLC raised its position in shares of MacroGenics by 36.9% during the 4th quarter. SG Americas Securities LLC now owns 28,589 shares of the biopharmaceutical company’s stock valued at $275,000 after acquiring an additional 7,712 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in MacroGenics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 30,085 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 7,629 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of MacroGenics by 0.8% during the third quarter. Vanguard Group Inc. now owns 4,414,924 shares of the biopharmaceutical company’s stock worth $20,574,000 after purchasing an additional 36,396 shares during the period. Finally, Wellington Management Group LLP lifted its position in shares of MacroGenics by 3.0% in the 3rd quarter. Wellington Management Group LLP now owns 248,520 shares of the biopharmaceutical company’s stock worth $1,158,000 after buying an additional 7,215 shares during the last quarter. Institutional investors own 96.89% of the company’s stock.

Analyst Ratings Changes

MGNX has been the subject of a number of recent research reports. B. Riley started coverage on shares of MacroGenics in a research report on Friday. They set a “buy” rating and a $25.00 price objective for the company. Barclays increased their price target on MacroGenics from $12.00 to $23.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. JMP Securities restated a “market outperform” rating on shares of MacroGenics in a research report on Thursday, April 4th. TD Cowen raised MacroGenics from a “hold” rating to a “buy” rating in a research report on Tuesday, April 9th. Finally, TheStreet cut MacroGenics from a “c” rating to a “d” rating in a research note on Thursday, March 7th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, MacroGenics currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

MacroGenics Stock Up 1.3 %

Shares of NASDAQ MGNX opened at $14.56 on Friday. The stock has a market cap of $910.87 million, a P/E ratio of -91.00 and a beta of 2.09. The firm’s 50-day simple moving average is $16.73 and its 200 day simple moving average is $11.91. MacroGenics, Inc. has a fifty-two week low of $4.29 and a fifty-two week high of $21.88.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.49). The company had revenue of $10.72 million for the quarter, compared to the consensus estimate of $25.70 million. MacroGenics had a negative return on equity of 88.49% and a negative net margin of 15.42%. During the same quarter last year, the firm posted $0.21 earnings per share. On average, sell-side analysts anticipate that MacroGenics, Inc. will post -2.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Jeffrey Stuart Peters sold 51,395 shares of MacroGenics stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $15.55, for a total transaction of $799,192.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, VP Jeffrey Stuart Peters sold 51,395 shares of the firm’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $15.55, for a total transaction of $799,192.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Ezio Bonvini sold 13,316 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $15.00, for a total transaction of $199,740.00. Following the completion of the sale, the senior vice president now owns 74,668 shares in the company, valued at $1,120,020. The disclosure for this sale can be found here. Insiders sold 80,835 shares of company stock worth $1,276,588 over the last ninety days. Company insiders own 11.30% of the company’s stock.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.